Show simple item record

dc.contributor.authorMcGrath, Emer R.
dc.contributor.authorKapral, Moira K.
dc.contributor.authorFang, Jiming
dc.contributor.authorEikelboom, John W.
dc.contributor.authoró Conghaile, Aengus
dc.contributor.authorCanavan, Michelle
dc.contributor.authorO’Donnell, Martin J.
dc.date.accessioned2018-09-20T16:17:10Z
dc.date.available2018-09-20T16:17:10Z
dc.date.issued2014-11-06
dc.identifier.citationMcGrath, Emer R. Kapral, Moira K.; Fang, Jiming; Eikelboom, John W.; ó Conghaile, Aengus; Canavan, Michelle; O’Donnell, Martin J. (2014). Antithrombotic therapy after acute ischemic stroke in patients with atrial fibrillation. Stroke 45 (12),
dc.identifier.issn0039-2499,1524-4628
dc.identifier.urihttp://hdl.handle.net/10379/12796
dc.description.abstractBackground and Purpose-For patients with atrial fibrillation and ischemic stroke (IS), current guidelines recommend oral anticoagulation (OAC) alone for secondary prevention of IS. In a large prospective cohort of patients with acute IS and atrial fibrillation, we determine the association between antithrombotic regimen on discharge and risk of major vascular events. Methods-Prospective cohort of consecutive patients included in the Ontario Stroke Registry. Multivariable Cox proportional hazard models were used to determine the association between antithrombotic regimen on discharge and time to death or admission for recurrent IS, myocardial infarction, or major bleeding. Results-Two thousand one hundred sixty-two patients were hospitalized atrial fibrillation and acute IS. At discharge, 8.0% were prescribed no antithrombotic therapy, 21.6% antiplatelet therapy alone, 39.3% OAC (warfarin) alone, and 31.1% combination OAC and antiplatelet therapy. Compared with OAC alone (hazard ratio [HR], 1.0), no antithrombotic therapy (HR, 1.51; 95% confidence interval, 1.23-1.86) and antiplatelet therapy (HR, 1.31; 95% confidence interval, 1.14-1.50) were associated with an increased risk of the primary composite outcome, whereas combination OAC and antiplatelet therapy was associated with a trend toward a reduced risk (HR, 0.91; 95% confidence interval, 0.80-1.04 overall and HR, 0.79; 95% confidence interval, 0.61-1.02 in those with coronary heart disease). Results were consistent in those with severe stroke: HR 1.58 (95% CI, 1.21-2.06), 1.34 (95% CI, 1.09-1.63), and 0.91 (95% CI, 0.74-1.11), respectively. Conclusions-Contrary to current guidelines, 30% of patients with atrial fibrillation and recent IS are not prescribed any OAC therapy on discharge, whereas a further 30% are prescribed combination OAC and antiplatelet therapy. Combination OAC and antiplatelet therapy in patients at high cardiovascular risk requires evaluation in clinical trials, particularly with the newer OACs, given their more favorable risk-benefit ratio compared with warfarin.
dc.publisherOvid Technologies (Wolters Kluwer Health)
dc.relation.ispartofStroke
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Ireland
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/ie/
dc.subjectatrial fibrillation
dc.subjectsecondary prevention
dc.subjectstroke
dc.subjectaspirin therapy
dc.subjectdose warfarin
dc.subjectprevention
dc.subjectrisk
dc.subjectanticoagulation
dc.subjecttrials
dc.subjectmetaanalysis
dc.subjectassociation
dc.subjectintensity
dc.subjectregistry
dc.titleAntithrombotic therapy after acute ischemic stroke in patients with atrial fibrillation
dc.typeArticle
dc.identifier.doi10.1161/strokeaha.114.006929
dc.local.publishedsourcehttps://www.ahajournals.org/doi/pdf/10.1161/STROKEAHA.114.006929
nui.item.downloads0


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Ireland
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland